| Ytd | -4.80% | |
| 1y | -40.50% |
| Open | 1.22 | Prev Close | 1.24 | Low | 1.19 | High | 1.25 | Mkt Cap | 17.71M |
| Vol | 251.04K | Avg Vol | 3.05M | EPS | -0.85 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 1.27 | Short Ratio | 1.41 | Inst. Own | 2.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.02 | 200-d Avg | 1.24 | 1yr Est | 25.00 |
BCDA News
Dear Fellow Shareholders,Upon completion of our recent capital raise, I am providing this update on
BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 r
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the t
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimal
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst cons
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consen
BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDR
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme
BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatm
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consen
This prospectus supplement updates and amends certain information in our base prospectus, dated Dece
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly los
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
During Tuesday's session, 275 companies made new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Monday's session saw 175 companies set new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
On Tuesday, 164 companies achieved new lows for the year.